FOLH1 and prostate carcinoma: Various cell surface markers have been evaluated for diagnosis and treatment of patients suffering from prostate cancer, including prostate specific antigen (PSA) [6], prostatic acid phosphatase (PAP) [7], prostate stem cell antigen (PSCA) [8], and prostate specific membrane antigen (PSMA) [9,10].